$119.02
0.86% today
Nasdaq, May 05, 05:49 pm CET
ISIN
IE00B4Q5ZN47
Symbol
JAZZ

Jazz Pharmaceuticals Plc Stock price

$120.05
-6.39 5.05% 1M
+10.64 9.72% 6M
-3.10 2.52% YTD
+10.76 9.85% 1Y
-37.25 23.68% 3Y
+11.32 10.41% 5Y
-63.18 34.48% 10Y
Nasdaq, Closing price Fri, May 02 2025
+2.87 2.45%
ISIN
IE00B4Q5ZN47
Symbol
JAZZ
Sector
Industry

Key metrics

Market capitalization $7.40b
Enterprise Value $10.57b
P/E (TTM) P/E ratio 13.80
EV/FCF (TTM) EV/FCF 7.79
EV/Sales (TTM) EV/Sales 2.60
P/S ratio (TTM) P/S ratio 1.82
P/B ratio (TTM) P/B ratio 1.78
Revenue growth (TTM) Revenue growth 6.12%
Revenue (TTM) Revenue $4.07b
EBIT (operating result TTM) EBIT $726.63m
Free Cash Flow (TTM) Free Cash Flow $1.36b
Cash position $2.99b
EPS (TTM) EPS $8.70
P/E forward 12.74
P/S forward 1.73
EV/Sales forward 2.47
Short interest 8.47%
Show more

Is Jazz Pharmaceuticals Plc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,785 stocks worldwide.

Jazz Pharmaceuticals Plc Stock Analysis

Unlock Scores for Free

Analyst Opinions

20 Analysts have issued a Jazz Pharmaceuticals Plc forecast:

18x Buy
90%
2x Hold
10%

Analyst Opinions

20 Analysts have issued a Jazz Pharmaceuticals Plc forecast:

Buy
90%
Hold
10%

Financial data from Jazz Pharmaceuticals Plc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
4,069 4,069
6% 6%
100%
- Direct Costs 1,073 1,073
3% 3%
26%
2,996 2,996
7% 7%
74%
- Selling and Administrative Expenses 725 725
13% 13%
18%
- Research and Development Expense 884 884
4% 4%
22%
1,387 1,387
7% 7%
34%
- Depreciation and Amortization 660 660
3% 3%
16%
EBIT (Operating Income) EBIT 727 727
10% 10%
18%
Net Profit 560 560
35% 35%
14%

In millions USD.

Don't miss a Thing! We will send you all news about Jazz Pharmaceuticals Plc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Jazz Pharmaceuticals Plc Stock News

Neutral
PRNewsWire
5 days ago
DUBLIN , April 30, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the BofA Securities 2025 Healthcare Conference. Company management will participate in a fireside chat on Wednesday, May 14, 2025, at 10:00 a.m.
Neutral
PRNewsWire
10 days ago
DUBLIN , April 25, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the conditional marketing authorization of zanidatamab, an investigational dual human epidermal growth factor receptor 2 (HER2)-targeted bispecific antibod...
Neutral
PRNewsWire
12 days ago
Statistically significant and clinically meaningful progression-free survival (PFS) and overall survival (OS) data for Zepzelca® (lurbinectedin) and atezolizumab (Tecentriq®) combination underscore potential of first-line maintenance therapy for extensive-stage small cell lung cancer, a much-needed advancement for patients Long-term outcomes and survival data for Ziihera ®  (zanidatamab-hrii)  ...
More Jazz Pharmaceuticals Plc News

Company Profile

Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: XYREM, ERWINAZETM, PRIALT, intrathecal infusion, FAZACLO and LUVOX CR. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Head office Ireland
CEO Bruce Cozadd
Employees 2,800
Founded 2005
Website www.jazzpharmaceuticals.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today